Ariana Boswell

All articles by Ariana Boswell

• FDA approves linerixibat to treat itching in PBC

  Linerixibat is the first drug approved in the United States to treat cholestatic pruritis in adults living with PBC.

• How to ‘Light Up for Rare’ on Rare Disease Day

  Landmarks worldwide will light up on Rare Disease Day.

• Recompensation possible in patients with decompensated PBC

  A recent study found that recompensation can be a useful clinical endpoint in patients with PBC and decompensated cirrhosis.

• Trying light therapy for PBC

  Light therapy may help ease fatigue and itching in PBC.

• Review: PPAR agonists outperform placebo in patients with PBC

  PPAR agonists reduced biomarkers of liver dysfunction compared to placebo across several clinical trials of patients with PBC.

• Study suggests more liver biomarkers should be monitored in PBC

  Alkaline phosphatase may not be the only liver biomarker that predicts the risk of negative outcomes in patients with PBC, a study found.

• Why was PBC called ‘primary biliary cirrhosis’?

  Although the change from “cirrhosis” to “cholangitis” may seem small, it represents decades of improved understanding.

• Study identifies potential biomarker of liver damage in PBC

  Compared to healthy controls, patients with early-stage PBC have altered expression of a class of molecules known as sphingolipids.

• Experts develop international guidelines for PBC consultations

  A group of 151 experts convened to develop a set of recommendations for primary biliary cholangitis (PBC) treatment and care.

• Linerixibat may reduce itching in patients with PBC

  The GLISTEN clinical trial found that patients with PBC who take linerixibat experience less itching and fewer sleep disturbances.